Mar 04, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 4, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL
Feb 24, 2026
WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026;
Feb 17, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Feb. 17, 2026-- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX ® (pitolisant) tablets for the treatment of cataplexy in pediatric
Feb 10, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Feb. 10, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets.
Jan 12, 2026
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy On Track to Extend the Pitolisant Franchise into the 2040s With Next-Gen Pitolisant Formulations Potential Best-In-Class Orexin-2 Agonist
Jan 07, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Jan. 7, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco . Jeffrey M. Dayno , M.D., President and Chief Executive Officer, is scheduled to present
